Tina Wu, MD
Clinician, Aluna Science
Tina Wu, MD, MBA, is Co-Founder and Chief Medical Officer of Aluna Science. Double board-certified in Emergency Medicine and Obesity Medicine, she practices as an attending physician and associate professor at the Greater Los Angeles VA Healthcare System.
Prior to founding Aluna Science, Dr. Wu held senior leadership roles at Cloud Health Medical Systems, Sunrise Health, and Waltz Health. She spent more than a decade at NYU Langone Health, serving as Associate Chief of Service in Emergency Medicine and Medical Director of Kimmel Pavilion 11. During the COVID-19 pandemic, she led an acute care unit, reinforcing her commitment to high-acuity and underserved patient populations.
Dr. Wu earned dual BA and BS degrees from the University of Arizona, an MBA from Harvard Business School, and an MD from the UCLA David Geffen School of Medicine. She completed her Emergency Medicine residency at NYU Langone/Bellevue and fellowships in global health and national security. She has published extensively and was named by Time Magazine among the “200 Brightest, Most Industrious Minds in America.”
Credentials & certifications
Undergraduate:
BA/BS in Molecular and Cellular Biology and Psychology from University of Arizona
Graduate:
MBA from Harvard Business School
Medical school:
MD from University of California, Los Angeles (UCLA) David Geffen School of Medicine
Residency:
Emergency Medicine at NYU Langone Health/Bellevue Hospital Center
Fellowships:
National Security Education Fellowship, American Medical Student Association (AMSA) Global Health Fellowship
Specialist areas
- Emergency Medicine
- Obesity Medicine
- Digital Health & Telemedicine
- Clinical Operations & Quality
Experience
Education & training
Featured publications
- The Use of an Emergency Department Expeditor to Improve Emergency Department CT Workflow: Initial ExperiencesGyftopoulos S, Wu TS, et al. | Journal of the American College of RadiologyView publication
- Progesterone receptor does not improve the performance and test effectiveness of the conventional 3-marker panel, consisting of estrogen receptor, vimentin and carcinoembryonic antigen….Liao CL, Lee MY, Tyan YS, Kok LF, Wu TS, et al. | May 28, 2009, Journal of Translational Medicine 2009, 7:37View publication
- Adding the p16(INK4a) marker to the traditional 3-marker (ER/Vim/CEA) panel engenders no supplemental benefit in distinguishing between primary endocervical and endometrial adenocarcinomas…Han CP, Lee MY, Kok LF, Ruan A, Wu TS, Cheng YW, Tyan YS, Lin CY | Sep 2009, Int J Gynecol Pathol. 28(5):489-96View publication
- Association Between Academic Medical Center Pharmaceutical Detailing Policies and Physician PrescribingIan Larkin, Desmond Ang, Jonathan Steinhart, Tina Wu, et al. | May 2, 2017, JAMA, Vol. 317, No. 17, pp. 1785–1795View publication
All publications
- Ancillary p16(INK4a) adds no meaningful value to the performance of ER/PR/Vim/CEA panel in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray study
Yao CC, Kok LF, Lee MY, Wang PH, Wu TS, Tyan YS, Cheng YW, Kung MF, Han CP | Sep 2009, Arch Gynecol Obstet. 280(3):405-13
- Scoring of p16(INK4a) immunohistochemistry based on independent nuclear staining alone can sufficiently distinguish between endocervical and endometrial adenocarcinomas in a tissue microarray study
Han CP, Kok LF, Wang PH, Wu TS, Tyan YS, Cheng YW, Lee MY, Yang SF | Jun 2009, Mod Pathol. 22(6):797-806
- Scoring mechanisms of p16INK4a immunohistochemistry based on either independent nucleic stain or mixed cytoplasmic with nucleic expression
Koo CL, Kok LF, Lee MY, Wu TS, Cheng YW, Hsu JD, Ruan A, Chao KC, Han CP | Apr 14, 2009, J Transl Med
- Comparing the scoring mechanisms of p16(INK4a) immunohistochemistry based on independent nucleic stains and independent cytoplasmic stains in distinguishing between endocervical and endometrial adenocarcinomas in a tissue microarray study
Kok LF, Lee MY, Tyan YS, Wu TS, Cheng YW, Kung MF, Wang PH, Han CP | May 6, 2009, Arch Gynecol Obstet
- Five commonly used markers (p53, TTF1, CK7, CK20, and CK34betaE12) are of no use in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray extension study
Han CP, Kok LF, Lee MY, Wu TS, Ruan A, Cheng YW, Wang PH, Koo CL, Tyan YS | May 15, 2009, Arch Gynecol Obstet
- The Medical Student Global Health Experience: Professional and Ethical Implications
Wu TS, Shah S | 2008, J Med Ethics
- Acute Stroke Care in a New York City Comprehensive Stroke Center during the COVID-19 Pandemic
Agarwal S, Sher E, Wu TS, et al. | Journal of Stroke and Cerebrovascular Diseases